NASDAQ:AGMB | News | Agomab Therapeutics NV

AGMB News

Official issuer or fund updates, exact SEC current reports, and large established publisher coverage, newest first. Every lawfully retained item remains in the corpus; each public page contains at most 100 rows. Headlines open the exact source; summaries are concise descriptions and not investment recommendations. Captured 2026-08-31.

DateTypePublisherHeadlineSummary
2026-08-10Foreign issuer reportSEC filingAgomab Therapeutics NV filed Form 6-KAgomab Therapeutics NV filed Form 6-K.
2026-08-06Foreign issuer reportSEC filingAgomab Therapeutics NV filed Form 6-KAgomab Therapeutics NV filed Form 6-K.
2026-06-23Foreign issuer reportSEC filingAgomab Therapeutics NV filed Form 6-KAgomab Therapeutics NV filed Form 6-K.
2026-05-27Foreign issuer reportSEC filingAgomab Therapeutics NV filed Form 6-KAgomab Therapeutics NV filed Form 6-K.
2026-04-24Foreign issuer reportSEC filingAgomab Therapeutics NV filed Form 6-KAgomab Therapeutics NV filed Form 6-K.
2026-03-05Foreign issuer reportSEC filingAgomab Therapeutics NV filed Form 6-KAgomab Therapeutics NV filed Form 6-K.
2026-02-09Foreign issuer reportSEC filingAgomab Therapeutics NV filed Form 6-KAgomab Therapeutics NV filed Form 6-K.